Following the Pfizer and AstraZeneca vaccinations, the World Health Organization on March 12 approved the Johnson & Johnson coronavirus vaccine for emergency use. In a statement, WHO chief Tedros Adhanom Ghebreyesus said all new, safe and effective devices against COVID-19 are another step closer to controlling the pandemic. The DA said the J&J had been issued with an “emergency use listing” which assesses the suitability of new health products in a public health emergency, and which is faster than the regular licensing system.
.@WHO listing gave emergency use to Johnson & Johnson’s # COVID19 vaccine, the first to be listed as a single-dose regimen. As new vaccines become available, we need to make sure they become part of the ð ?????? solution, & it is not another reason that some countries and peoples are left further afield.
– Tedros Adhanom Ghebreyesus (@DrTedros) March 12, 2021
The J&J vaccine license has now paved the way for the use of the jobs as part of a COVAX initiative aimed at ensuring fair access to vaccines in poor countries. Approximately 500 million doses of Johnson & Johnson jabs have been pledged to the facility and the WHO hopes to be able to apply through the scheme from July, if not earlier. Speaking at a press conference, Tedros said the WHO hopes this new vaccine will help reduce, and not deepen, vaccine inequality.
EU approves J&J vaccine
Meanwhile, EUA WHO comes after the single-dose injection received approval from the European Union on Thursday. The vaccine, made by Janssen, is safe and effective and is considered to be flexible. It is worth noting that the Johnson & Johnson vaccine, in a large study, spanning three continents, has been strong even in countries including South Africa.
According to the FDA, the Johnson & Johnson vaccine has been tested in more than 44,000 people in the U.S., South Africa, and Latin America. Globally, the 66.1 percent vaccine was effective against moderate to severe COVID-19 / at least four weeks after vaccination. In the U.S., however, the vaccine is considered 72 percent effective and offers 86 percent protection against malignant forms of the disease.